skip to content
Everolimus (Afinitor) (oral tablets). Preview this item
ClosePreview this item
Checking...

Everolimus (Afinitor) (oral tablets).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, September 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
The objective of this review is to perform a systematic review of the beneficial and harmful effects of everolimus for the treatment of patients three years of age or older with subependymal giant cell astrocytoma (SEGAs) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgery is not required.
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Systematic Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1076548007
Description: 1 online resource (1 PDF file (viii, 46 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: CDR clinical review report for Afinitor

Abstract:

The objective of this review is to perform a systematic review of the beneficial and harmful effects of everolimus for the treatment of patients three years of age or older with subependymal giant cell astrocytoma (SEGAs) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgery is not required.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1076548007> # Everolimus (Afinitor) (oral tablets).
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "1076548007" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/5592578836#Topic/administration_oral> ; # Administration, Oral
    schema:about <http://experiment.worldcat.org/entity/work/data/5592578836#Topic/astrocytoma_drug_therapy> ; # Astrocytoma--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/5592578836#Topic/antineoplastic_agents_therapeutic_use> ; # Antineoplastic Agents--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/5592578836#Topic/everolimus> ; # Everolimus
    schema:about <http://experiment.worldcat.org/entity/work/data/5592578836#Topic/tuberous_sclerosis> ; # Tuberous Sclerosis
    schema:alternateName "CDR clinical review report for Afinitor" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/5592578836#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "The objective of this review is to perform a systematic review of the beneficial and harmful effects of everolimus for the treatment of patients three years of age or older with subependymal giant cell astrocytoma (SEGAs) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgery is not required."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/5592578836> ;
    schema:genre "Systematic Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/5592578836#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "Everolimus (Afinitor) (oral tablets)."@en ;
    schema:productID "1076548007" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK525620/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1076548007> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/5592578836#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/5592578836#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1076548007> ; # Everolimus (Afinitor) (oral tablets).
    schema:name "Common drug review clinical review report." ;
    schema:name "Common drug review clinical review report" ;
    .

<http://experiment.worldcat.org/entity/work/data/5592578836#Topic/administration_oral> # Administration, Oral
    a schema:Intangible ;
    schema:name "Administration, Oral"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5592578836#Topic/antineoplastic_agents_therapeutic_use> # Antineoplastic Agents--therapeutic use
    a schema:Intangible ;
    schema:name "Antineoplastic Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5592578836#Topic/astrocytoma_drug_therapy> # Astrocytoma--drug therapy
    a schema:Intangible ;
    schema:name "Astrocytoma--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5592578836#Topic/tuberous_sclerosis> # Tuberous Sclerosis
    a schema:Intangible ;
    schema:name "Tuberous Sclerosis"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.